Enoxaparin effect on malondialdehyde levels in laparoscopic cholecystectomy

Area of Science:

• Biochemistry
• Surgical Research
• Pharmacology

Background:

• Ischemia-reperfusion injury is a concern during laparoscopic cholecystectomy.
• Plasma malondialdehyde (MDA) is a marker of oxidative stress.
• Investigating protective agents against ischemia-reperfusion injury is crucial.

Purpose of the Study:

• To evaluate the effect of low-dose enoxaparin on plasma MDA levels during laparoscopic cholecystectomy.
• To assess enoxaparin's impact on ischemia-reperfusion-induced oxidative stress.
• To determine if enoxaparin influences liver enzyme levels (ALT, AST) in this context.

Main Methods:

• Fifty patients undergoing laparoscopic cholecystectomy were randomized into two groups.
• The enoxaparin group received 20 mg subcutaneous enoxaparin 2 hours pre-surgery.
• Blood samples were collected to measure MDA, ALT, and AST at specific surgical time points.

Main Results:

• Plasma MDA levels did not differ significantly between groups pre-operatively or before deflation.
• MDA levels significantly increased in the control group post-deflation (p=0.049), but not in the enoxaparin group.
• Both groups showed similar increases in ALT and AST levels, without significant differences between them.

Conclusions:

• Low-dose subcutaneous enoxaparin administered pre-operatively can prevent MDA elevation during reperfusion after laparoscopic cholecystectomy.
• Enoxaparin did not induce bleeding complications or alter the expected increase in ALT and AST levels.
• This suggests a protective role for low-dose enoxaparin against oxidative stress in this surgical model.